Vaishali Pharma Ltd.
(Formerly known as Vaishali Pharma Pvt. Ltd.)

RATED
ISO 9001 ISC GLOBAL
GOVT. RECOGNIZED STAR EXPORT HOUSE

CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

Date: 06th February, 2020

To,
National Securities Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 4000513

Sub: Press Release Dt 06.02.2020

NSE Symbol : VAISHALI NSE Series : EQ

Dear Sir,

Please find attached Media Release dated 06th February 2020, which is Self-Explanatoryfor your kind perusal and records

Thanking you,
Yours Faithfully
For VAISHALI PHARMA LIMITED

Atul Vasani
Chairman and Managing Director

VAISHALI PHARMA LTD * MUMBAI *

Encl : a/a

Media Release

3 New Product Registrations received in developing market of Myanmar

Mumbai, Feb 06, 2020: Vaishali Pharma Limited (*NSE: VAISHALI*), abided by the norms of extending uncompromised quality products, has raised the standards of the industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

The Company has over 120+ formulation brands being marketed in multiple countries; with dossier in CTD/ACTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with their clients. Passionate to be the best, Vaishali Pharma takes pride in what the Company does and strives to deliver products with zero defects.

Recently, Company has received registration for three products (i.e. VMOX CV-1200, VMOX CV-600, and CYBUFIN-1500) in the Myanmar market. These products have a good demand in the local market of Myanmar. This remarkable achievement in the Myanmar market symbolizes a landmark and enables the Company to reach out more and strengthen its presence in the high growth market of Myanmar. This signifies a momentous achievement and enables the Company to reach out to more and more territories to strengthen its presence in key markets of these regions.

Following are the products which have received registrations:

Sr. No	Product Name	Country	Packing Type	Therapeutic Usage
1	VMOX CV-1200	Myanmar	Injection	Antibiotic
2	VMOX CV-600	Myanmar	Injection	Antibiotic
3	CYBUFIN-1500	Myanmar	Injection	Antibiotic

Management Comment:

Commenting on the recent development, Mr. Atul Vasani, Chairman and Managing Director, Vaishali Pharma Limited said:

"We are very happy to share that our Company has received three new product registrations in high growth market of Myanmar. These products of VMOX CV-1200, VMOX CV-600, and CYBUFIN-1500 have a very good demand in the Myanmar market. This remarkable achievement will further strengthen the Company's presence in Myanmar market and enhance stronger relations with our clients. Our Company will benefit from the larger sale of products in these markets. This is yet another important step towards laying a strong foundation and meeting our desired targets. Our Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.

I would like to thank the entire team of 'Vaishali Pharma Ltd.' for their untiring efforts, hard work, sincerity and high dedication."

About Vaishali Pharma Limited:

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products, with a well-established brand known for its high-quality products & services amongst various clients globally.

The company has over 120+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our offices are also located in Vietnam. Further widening our reach overseas, the Company made a joint venture with D.R. Congo based company. The Company exports to countries like Russia, Cameroon, Madagascar, Kenya, Myanmar, Vietnam, ,Ghana, Costa-Rica, Nicaragua ,D.R. Congo, Zimbabwe, Nigeria, Angola, Armenia, Tajikistan, Turkmenistan, Iraq, Afghanistan, Sri-lanka, Cambodia, Papua New Guinea, Egypt, Morocco, etc. and also having Mix portfolio under registration in other 10 countries. With this we are expanding and penetrating the market helping us to develop our brand across globe in 20+ countries.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Mr.Atul Vasani

Chairman and Managing Director

Vaishali Pharma Limited

Email: director@vaishalipharma.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*